PRTA vs. XNCR, MNKD, BLTE, MIRM, ABCL, GMTX, COLL, DCPH, PIRS, and MGNX
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Xencor (XNCR), MannKind (MNKD), Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), Pieris Pharmaceuticals (PIRS), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry.
Prothena (NASDAQ:PRTA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
In the previous week, Prothena had 3 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Prothena and 1 mentions for Xencor. Xencor's average media sentiment score of 1.76 beat Prothena's score of -0.26 indicating that Xencor is being referred to more favorably in the news media.
Prothena has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
Prothena currently has a consensus target price of $68.14, indicating a potential upside of 226.51%. Xencor has a consensus target price of $36.00, indicating a potential upside of 80.18%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Xencor.
Prothena received 107 more outperform votes than Xencor when rated by MarketBeat users. However, 72.85% of users gave Xencor an outperform vote while only 70.60% of users gave Prothena an outperform vote.
Xencor has higher revenue and earnings than Prothena. Xencor is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Xencor has a net margin of -74.90% compared to Prothena's net margin of -160.91%. Xencor's return on equity of -18.67% beat Prothena's return on equity.
97.1% of Prothena shares are owned by institutional investors. 28.2% of Prothena shares are owned by company insiders. Comparatively, 5.0% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Xencor beats Prothena on 11 of the 18 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
